Evidence map›Paper›PMID 37576075›Full record

ArticleInternational journal of cardiology. Heart & vasculature2023

Outcomes and survival of patients undergoing percutaneous vegetectomy for right heart endocarditis.

Maria Riasat, Balaram Krishna J Hanumanthu, Arshan Khan, Abdul Haseeb Riaz, Zauraiz Anjum, Moiz Ehtesham, Saif Ur Rehman, Ayesha Javed, Abdullah Muhammad, Deepika Misra

Abstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. A Retrospective Analysis of AngioVac Outcomes at a Tertiary Care Center.Journal of the Society for Cardiovascular Angiography & Interventions · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maria RiasatDepartment of Internal Medicine, Mount Sinai Beth Israel, Manhattan, NY, United States.
Balaram Krishna J HanumanthuDepartment of Cardiology, Mount Sinai Beth Israel, Manhattan, NY, United States.
Arshan KhanDepartment of Internal Medicine, Ascension St. John Hosp, Grosse Pointe, MI, United States.
Abdul Haseeb RiazDepartment of Internal Medicine, Cape Fear Valley Medical Ctr, North Carolina, NC, United States.
Zauraiz AnjumDepartment of Internal Medicine, Rochester General Hosp, Rochester, NY, United States.
Moiz EhteshamDepartment of Internal Medicine, Albany Medical Center, Albany, NY, United States.
Saif Ur RehmanDepartment of Internal Medicine, Rochester General Hosp, Rochester, NY, United States.
Ayesha JavedDepartment of Medicine, King Edward Medical University, Pakistan.
Abdullah MuhammadDepartment of Internal Medicine, Henry Ford Jackson, MI, United States.
Deepika MisraDepartment of Cardiology, Mount Sinai Beth Israel, Manhattan, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Backgrounds: AngioVac is used for the percutaneous removal of vegetations and for debulking of large vegetations in patients who are not surgical candidates.This study aims to identify the demographics, echocardiographic features, indications, improvement of the tricuspid valve regurgitation, and survival outcomes of patients who have undergone AngioVac vegetectomy reported in the literature. Methods: A systematic review was performed to identify articles reporting suction thromectomy or vegetation removal using the AngioVac system for RSIE (right sided infective endocarditis). Survival on discharge was our primary outcome. Additionally, we evaluated indications for suction thrombectomy and TR improvement. Categorical variables were expressed as percentages and ratios. Results: A total of 49 studies were identified. The most common risk factor was intravenous drug abuse seen in 45% (20/49) and cardiovascular implantable electronic device (CIED) in 45% (20/49). Circulatory shock was seen in 35% of patients. The causative organism was gram positive cocci (86%). Moderate to severe TR was present in 74% of cases with documented echocardiograms. Indications for AngioVac were poor surgical candidacy (81%) or to reduce septic emboli risk (19%). Survival at discharge was 93%. TR improvement was reported only in 16% cases and remained unchanged/worsened in 84%. Conclusion: AngioVac procedure is an alternative treatment for critically ill patients who cannot undergo surgery. To understand the survival, safety and candidacy of patients undergoing this procedure, further randomized control studies and literature reviews are needed. The improvement or worsening of tricuspid regurgitation in patients with TR valve involvement is another factor to be investigated.

Indexed as

Outcomes/SurvivalRight hear endocarditisSuction thrombectomyTricuspid valve regurgitation

Identifiers

PMID37576075
PMCPMC10422668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.